Best Evidence Analyses and Commentary

Array ( [a] => displayArticle [aFeedID] => 3101 [aArticleID] => 20179 [aCID] => 240 [aAID] => 0 [DF] => THSBDA [DT] => P ) Notice: Undefined index: n in /home/mutualgravity/public_html/archangel/feedengine/content.php on line 16 Notice: Undefined index: so in /home/mutualgravity/public_html/archangel/feedengine/content.php on line 17 Notice: Undefined index: sh in /home/mutualgravity/public_html/archangel/feedengine/content.php on line 18
FDA Approves Teflaro for Bacterial Infections
November 05, 2010

The U.S. Food and Drug Administration today approved Teflaro (ceftaroline fosamil), an injectable antibiotic to treat adults with community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA).

Teflaro is an antibacterial agent in a class of drugs known as cephalosporins, which act by interfering with the bacterial cell wall.

CABP is a bacterial infection that develops in the lungs of patients who are exposed to the bacteria in their normal environment, and not in the hospital. ABSSSI is a bacterial infection of skin and skin structures that requires antibiotic treatment and may require surgical treatment.

MRSA is a type of staph bacteria that is resistant to certain antibiotics. These antibiotics include methicillin and other more common antibiotics such as oxacillin, penicillin, and amoxicillin. In the community, most MRSA infections are skin infections. Severe or potentially life-threatening MRSA infections occur most frequently among patients in contact with health care settings, according to the Centers for Disease Control and Prevention.

For more information, please visit: Teflaro


Website Terms of Use Disclaimer | E-mail Terms of Use | Contact LECOM | RSS | Copyright © 2009 LECOM - All rights reserved